[Experience in long-term use of berodual in the treatment of patients with chronic obstructive bronchitis].
To study clinical efficiency of 12-month administration of berodual in chronic obstructive bronchitis (COB). The trial entered 33 patients with at least 2-year history of COB and forced expiratory volume per 1 sec (FEV1) not less than 45% of normal value. The best response of clinical parameters and external respiration was observed throughout 3 weeks of berodual inhalations. Dyspnea and cough were cured by the end of the treatment in 40 and 26% of the patients, respectively. Exercise tolerance has improved, FEV1 has increased for the year from 71.9 to 79.1%. Long-term berodual monotherapy is able to inhibit progression of bronchial obstruction and symptoms of COB.